Aqua Bio Technology — Investor Presentation 2015

May 13, 2015

First Quarter 2015 Results Presentation

13 May 2015

Q1 2015 Highlights

• Revenue stream as agreed in exclusivity contracts
• Second best quarterly result in Company history
• Financial position further strengthened
• NOK 34 million cash reserve

Income Statement

NOK million	Q1 2015	Q1 2014	FY 2014
Income	9.1	5.4	22.5
Operating costs	-3.8	-4.2	-16.7
EBITDA	5.2	1.2	5.8
EBIT	3.6	-0.4	-0.5
EBT	4.1	-0.4	0.9
Net result	4.1	-0.4	0.9

EBITDA margin	57.7%	21.8%	26.0%

• Royalty and exclusivity payments received according to contracts
• Revenues may fluctuate significantly from quarter to quarter

70,0 %

Financial development last five quarters

Sales EBITDA

6000

Balance Sheet

NOK million	31 Mar 2015	31 Dec 2014	31 Mar 2014
Fixed assets	11.3	12.4	16.4
Current assets	67.2	63.4	60.5
- of which is cash	33.8	29.2	26.6
Total equity	70.4	66.3	65.6
Long term debt	5.6	5.6	8.5
Short term debt	2.5	3.9	2.8
Total balance	78.5	75.8	76.9
Equity ratio	89.7%	73.8%	85.3%

Cash flow

NOK million (Year to date)	2015	2014
Cash at beginning of period	29.2	27.0
From operations	4.7	1.5
From investments	-0.5	-1.4
From financing	-0.1	-0.6
Currency effects	0.5	0.0
Cash at end of period	33.8	26.6
Cash change in period	4.1	-0.4

A strategy for expansion

1.	Support exclusivity partners Restorsea and Amway in their efforts to reach commercial success in the cosmetics market with skin care products based on ABT technology.	Ongoing
2.	Active in-licensing of relevant technologies from partners; develop ABT as a powerhouse in commercializing third party technologies for skin care and other applications.	Ongoing
3.	Explore possible applications for medical use.	Initiated

Addressing a broader market

• ABT ingredients for medical purposes to be explored
• ABTs key personnel have experience from the pharmaceutical industry
• Natural and sustainable ingredients in demand also by medical/OTC products manufacturers

Outlook

• Continued strong revenue stream
• Commercial success of exclusivity partners represent upside potential
• Operating costs expected back to normal levels
• Limited marketing costs expected in first half 2015
• Strategy of broadened market approach holds potential
• Search, and evaluation of in-licensing candidates continues
• Medical market may represent significant long term potential
• Other market segments under review
• Robust financial position
• Equity ratio 90 pst; strong cash position

2nd Quarter 2015 Results 19 August 2015

Investor contact

Arvid Lindberg, CEO +47 9824 5410 arvid@aquabiotech.no

www.aquabiotechnology.com